Article

T-Cell-Mediated Killing in Glioblastoma Organoids induced by Adenoviral Delivery of the CIITA Transgene

2024-01-26

Abstract excerpt

<h4>ABSTRACT</h4> The immunosuppressive nature of the tumor microenvironment poses a significant challenge to effective immunotherapies against glioblastoma (GB). Boosting the immune response is critical for a successful therapy. Here, we adopted a cancer gene therapy approach to induce T-cell mediated killing of the tumor through increased activation of the immune system. Patient-based 3D GB models were infected...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b5124713-7f6b-5b07-8df7-40cdc06652f7
DOI: 10.1101/2024.01.22.576747

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

T-Cell-Mediated Killing in Glioblastoma Organoids induced by Adenoviral Delivery of the CIITA TransgeneDOI 10.1101/2024.01.22.576747Read

Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITASemantic proximity Read

Intratumoral gene delivery of 4-1BBL boosts IL-12-triggered anti-glioblastoma immunitySemantic proximity Read

CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockadeSemantic proximity Read

Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic VirotherapySemantic proximity Read

Virus-Based Therapies for the Treatment of Recurrent High-Grade GliomaSemantic proximity Read

IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastomaSemantic proximity Read

Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant GliomaSemantic proximity Read

A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injectionSemantic proximity Read

Active immunotherapy: oncolytic virus therapy using HSV-1.Semantic proximity Read

CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor VaccineSemantic proximity Read

A dual pronged approach to cancer immune exclusion: tumor-derived LAIR-1 simultaneously drives fibrosis and blocks immune recruitment in gliomaSemantic proximity Read

Therapeutic efficacy of an immune stimulatory gene therapy strategy in a mouse model of high grade brainstem gliomaSemantic proximity Read